Predominant Founder Effect among Recurrent Pathogenic Variants for an X-Linked Disorder.

ACMG/AMP variant interpretation guideline RS1 X-linked disorder X-linked retinoschisis (XLRS) founder effect haplotype analysis variant classification

Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
12 04 2022
Historique:
received: 07 03 2022
revised: 06 04 2022
accepted: 06 04 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 27 4 2022
Statut: epublish

Résumé

For disorders with X-linked inheritance, variants may be transmitted through multiple generations of carrier females before an affected male is ascertained. Pathogenic

Identifiants

pubmed: 35456481
pii: genes13040675
doi: 10.3390/genes13040675
pmc: PMC9029724
pii:
doi:

Substances chimiques

Eye Proteins 0

Banques de données

ClinicalTrials.gov
['NCT02471287', 'NCT00378742']

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Intramural NIH HHS
ID : ZIA EY000565
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA EY000564
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIC EY000478
Pays : United States

Références

Arch Ophthalmol. 2008 Mar;126(3):424-5
pubmed: 18332328
Nat Biotechnol. 2000 Feb;18(2):233-4
pubmed: 10657137
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Curr Opin Ophthalmol. 2012 Sep;23(5):355-63
pubmed: 22847030
Mol Ther. 2018 Sep 5;26(9):2282-2294
pubmed: 30196853
BMC Med Genet. 2019 Aug 14;20(1):139
pubmed: 31412794
Ann Oncol. 2007 Jun;18 Suppl 6:vi93-8
pubmed: 17591843
PLoS One. 2016 Jan 26;11(1):e0147653
pubmed: 26812435
Hum Mutat. 2003 Jun;21(6):577-81
pubmed: 12754702
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Genome Res. 2007 Dec;17(12):1783-6
pubmed: 17989245
Br J Ophthalmol. 2009 May;93(5):692-6
pubmed: 18617546
Hum Mol Genet. 2013 Dec 1;22(23):4756-67
pubmed: 23847049
Mol Genet Genomic Med. 2020 Oct;8(10):e1421
pubmed: 33460243
Clin Genet. 2013 Aug;84(2):190-7
pubmed: 23662816
Hum Mutat. 2020 Sep;41(9):1528-1539
pubmed: 32531846
Can J Ophthalmol. 1973 Jul;8(3):385-93
pubmed: 4742888
Int J Mol Sci. 2020 Feb 13;21(4):
pubmed: 32070051
Hum Mol Genet. 2002 Nov 15;11(24):3097-105
pubmed: 12417531
Hum Mutat. 2009 Dec;30(12):1657-66
pubmed: 19937601
Biotechniques. 2006 Aug;41(2):177-81
pubmed: 16925019
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Am J Hum Genet. 2016 Nov 3;99(5):1034-1044
pubmed: 27745835
Proc Natl Acad Sci U S A. 2016 May 10;113(19):5287-92
pubmed: 27114531
Hum Mutat. 2001 Aug;18(2):109-19
pubmed: 11462235
JAMA. 2006 Mar 22;295(12):1428-33
pubmed: 16551715
Genes (Basel). 2020 Feb 27;11(3):
pubmed: 32120898
Nat Methods. 2010 Aug;7(8):575-6
pubmed: 20676075
Mol Genet Metab. 2020 Feb;129(2):150-160
pubmed: 31519519
Am J Hum Genet. 2016 Jun 2;98(6):1077-1081
pubmed: 27236918
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
JAMA. 2007 Feb 21;297(7):733-6
pubmed: 17315303
Nat Struct Mol Biol. 2012 Jun 17;19(7):719-21
pubmed: 22705790
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Cold Spring Harb Perspect Med. 2015 Jun 22;5(8):a017368
pubmed: 26101206
Hum Mol Genet. 1998 Jul;7(7):1185-92
pubmed: 9618178
Adv Exp Med Biol. 2018;1085:43-48
pubmed: 30578483
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Bioinformatics. 2018 Mar 15;34(6):920-927
pubmed: 29092009
Genet Med. 2020 Jul;22(7):1156-1174
pubmed: 32284538
Eur J Hum Genet. 1999 Apr;7(3):368-76
pubmed: 10234514
Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4342-50
pubmed: 19324861
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669

Auteurs

Chelsea Bender (C)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Elizabeth Geena Woo (EG)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Bin Guan (B)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Ehsan Ullah (E)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Eric Feng (E)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Amy Turriff (A)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Santa J Tumminia (SJ)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Paul A Sieving (PA)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
UC Davis Medical Center, Ophthalmology & Vision Sciences, University of California, Davis, CA 95817, USA.

Catherine A Cukras (CA)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Robert B Hufnagel (RB)

National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH